PLOS ONE Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-analysis

Manuscript Number: PONE-D-14-21052R1 Article Type: Research Article Full Title: Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-analysis Short Title: TLR4 polymorphisms and aggressive prostate cancer Corresponding Author: Yen-Ching Chen, ScD Institute of Epidemiology and Preventive Medicine Taipei, NA TAIWAN

[1]  D. Lio,et al.  Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments , 2014, Cancer Gene Therapy.

[2]  Hongxia Ma,et al.  Association of TLR2 and TLR4 Polymorphisms with Risk of Cancer: A Meta-Analysis , 2013, PloS one.

[3]  Kui Zhang,et al.  The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. , 2013, European journal of cancer.

[4]  Christophe G. Lambert,et al.  Technical Reproducibility of Genotyping SNP Arrays Used in Genome-Wide Association Studies , 2012, PloS one.

[5]  Yuan Yuan,et al.  Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in cancer: a meta-analysis. , 2012, Gene.

[6]  P. Kraft,et al.  Genetic variation in the toll‐like receptor 4 and prostate cancer incidence and mortality , 2012, The Prostate.

[7]  M. Kattan,et al.  New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort , 2011, Cancer biology & therapy.

[8]  M. Thun,et al.  Genome-wide association study identifies new prostate cancer susceptibility loci. , 2011, Human molecular genetics.

[9]  J. Stanford,et al.  Genome-wide Association Study Identifies a Genetic Variant Associated with Risk for More Aggressive Prostate Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[10]  M. Pittler.  Systematic Reviews in Health Care: Meta‐analysis in Context , 2010 .

[11]  H. Grönberg,et al.  Sequence Variants in the TLR4 and TLR6-1-10 Genes and Prostate Cancer Risk. Results Based on Pooled Analysis from Three Independent Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[12]  C. Caruso,et al.  A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. , 2010, Current pharmaceutical design.

[13]  Hai-mou Zhang,et al.  Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. , 2009, Molecular immunology.

[14]  Kevin M. Bradley,et al.  Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes , 2009, Cancer Epidemiology Biomarkers & Prevention.

[15]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[16]  W. Isaacs,et al.  Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.

[17]  C. Caruso,et al.  TLR4 Polymorphisms and Ageing: Implications for the Pathophysiology of Age-Related Diseases , 2009, Journal of Clinical Immunology.

[18]  Choung-Soo Kim,et al.  The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. , 2009, Cancer genetics and cytogenetics.

[19]  R. Silverman,et al.  Inflammation, infection, and prostate cancer , 2008, Current opinion in urology.

[20]  M. Netea,et al.  Functional Consequences of Toll-like Receptor 4 Polymorphisms , 2008, Molecular medicine.

[21]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[22]  E. El-Omar,et al.  Polymorphisms in Toll-like receptor genes and risk of cancer , 2008, Oncogene.

[23]  Dweepanita Das,et al.  BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages , 2007, Journal of Virology.

[24]  J. Carpten,et al.  Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. , 2007, Journal of the National Cancer Institute.

[25]  Daniel Levy,et al.  A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study , 2007, BMC Medical Genetics.

[26]  Uzma Alam,et al.  Immunity: The Immune Response to Infectious and Inflammatory Disease , 2007, The Yale Journal of Biology and Medicine.

[27]  J. Witte,et al.  COX2 genetic variation, NSAIDs, and advanced prostate cancer risk , 2007, British Journal of Cancer.

[28]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[29]  E. Platz,et al.  Inflammation in the etiology of prostate cancer: an epidemiologic perspective. , 2007, Urologic oncology.

[30]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[31]  J. Witte,et al.  Toll-Like Receptor 4 Genetic Variation and Advanced Prostate Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[32]  Ben A. Rissing,et al.  Cardiovascular Diabetology BioMed Central Original investigation Increased proinflammatory endothelial response to S100A8/A9 , 2006 .

[33]  D. Hunter,et al.  Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. , 2005, Cancer research.

[34]  B. Wells,et al.  Prostate cancer and sexually transmitted diseases: a meta-analysis. , 2005, Family medicine.

[35]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[36]  E. Giovannucci,et al.  The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  Julian P T Higgins,et al.  Controlling the risk of spurious findings from meta‐regression , 2004, Statistics in medicine.

[38]  H. Grönberg,et al.  Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. , 2004, Cancer research.

[39]  Deborah F. Smith,et al.  Toll-Like Receptor 4 Contributes to Efficient Control of Infection with the Protozoan Parasite Leishmania major , 2004, Infection and Immunity.

[40]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[41]  J. Witztum,et al.  Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells* , 2003, The Journal of Biological Chemistry.

[42]  A. Seftel.  Meta-analysis of measures of sexual activity and prostate cancer. , 2002, The Journal of urology.

[43]  F. Van de Werf,et al.  Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[44]  C. Pan,et al.  Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. , 2001, Anticancer research.

[45]  N. Rothman,et al.  Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. , 2000, Journal of the National Cancer Institute.

[46]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[47]  G. Reaven,et al.  Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[48]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[49]  D. Alkon,et al.  Late memory-related genes in the hippocampus revealed by RNA fingerprinting. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[51]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[52]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.